Details of Viral Vaccine
This Viral vaccine card gives comprehensive information about each vaccine.
| Detailed Information | |
|---|---|
| ID | 10212 |
| Vaccine Name | MV-LASV (V182-001) |
| Disease Name | Lassa fever |
| Disease Classification | Hemorrhagic |
| Virus Name | Lassa virus |
| Nucleic Acid Content | negative-sense, single-stranded RNA |
| Vaccine Type | Live-attenuated |
| Vaccine Status | Phase 1 |
| Manufacturer | Themis Bioscience |
| Year of Manufacturing | 2021 |
| Manufacturing Country | Belgium |
| Age | 18 - 55 years |
| Dosage | 2 doses 28 days apart |
| Administration Route | Intramuscular |
| Adjuvant | NA |
| Target Strain | Measles Schwarz virus strain for prophylaxis of Lassa infection |
| Description | NA |
| Approving Organisation | NA |
| Collaborating Organisation | NA |
| Other Countries | NA |
| Trade Name | NA |
| PMID | NA |
| Clinical Trial ID | NCT04055454 |
| Reference Link | https://clinicaltrials.gov/ct2/show/NCT04055454?cond=Lassa+fever&draw=2&rank=10 |
| Additional Links | NA |